Cerevel notches Phase 3 Parkinson’s win ahead of AbbVie transaction closing
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients taking the biotech’s once-daily drug, called tavapadon, on top of the already approved Parkinson’s treatment levodopa saw a statistically significant increase of 1.1 more hours of